Staging Website
This page is connected to a test database. Data is not necessarily up-to-date and could be wiped out at any time.
Evidence matters. Find policies, programs, and systems changes that are a good fit for your community priorities.

Naloxone education & distribution programs

Evidence Rating
Strategies with this rating are most likely to make a difference. These strategies have been tested in many robust studies with consistently positive results.
Disparity Rating
Strategies with this rating have the potential to decrease or eliminate disparities between subgroups. Rating is suggested by evidence, expert opinion or strategy design.
Community Conditions
Alcohol and drug use
Societal Rules
Laws and policies
Authors
Lead: Naiya Patel
Contributor(s): Lael Grigg, Bomi Kim Hirsch
Acknowledgements: Kate Austin Stanford, Alison Bergum, Ksenia Kostelanetz, Jessica Rubenstein
Date Last Updated
April 22, 2024

Naloxone, or Narcan, is a medication that reverses overdoses caused by opioids such as heroin, Vicodin, and OxyContin; it is not a controlled substance and does not have potential for abuse (NPHL-Naloxone access laws, NPHL-Good Samaritan laws, SAMHSA-Overdose). Two naloxone products, an intranasal spray and an autoinjector for intramuscular or subcutaneous administration, have been approved by the U.S. Federal Drug Administration (FDA) for community use (Dunn 2017). As of 2020, all states and Washington, D.C. have naloxone access laws that increase naloxone dispensing from pharmacies to people at risk of an opioid overdose, to people who are likely to encounter someone who might overdose, or to distribution centers (Evoy 2021). States and communities can further expand access to naloxone through education, training, and distribution programs that reach people who misuse opioids and their families and friends (TFAH-Levi 2013, NPHL-Naloxone access laws) and efforts to ensure that all first responders are trained and authorized to administer naloxone (Davis 2014b, NPHL 2021).

Opioids refer to all natural, semisynthetic, and synthetic opioids available, while opiates refer to naturally occurring opioids like heroin, morphine, and codeine.

What could this strategy improve?

Expected Benefits

Our evidence rating is based on the likelihood of achieving these outcomes:

  • Increased knowledge of appropriate overdose response

Potential Benefits

Our evidence rating is not based on these outcomes, but these benefits may also be possible:

  • Reduced overdose deaths
  • Increased self-confidence

What does the research say about effectiveness? -+

There is strong evidence that opioid overdose education and naloxone distribution programs increase knowledge of appropriate overdose response among participants with substance use disorders and other participants who are likely to encounter an overdose situation (Jones 2022b, Rawal 2023, Razaghizad 2021, Winhusen 2020, Clark 2014, Giglio 2015, Lewis 2016, Ashrafioun 2016, Lott 2016). Naloxone distribution through such programs is associated with reduced opioid overdose deaths (Razaghizad 2021, Chimbar 2018, Giglio 2015, Walley 2013), increased opioid overdose reversal (Rawal 2023), and increased self-confidence in participants’ ability to respond effectively to overdoses (Razaghizad 2021, Ashrafioun 2016, Wagner 2016, Strang 2008). Education for pharmacists and primary care providers appears to have positive effects on Naloxone prescribing and dispensing rates, while also decreasing opioid drug prescribing over time (Kulbokas 2021).

Communities that implement programs to train potential bystanders (e.g., social service staff, individuals with a substance use disorder, and their family and friends) to identify an opioid overdose and respond with naloxone appear to reduce opioid overdose death rates more than communities that do not implement such programs (Walley 2013). In New York, community members attending Opioid Overdose Education and Naloxone Distribution (OEND) training programs improved their knowledge and attitudes about opioid overdose (Heavey 2018). Family and friends of individuals with a substance use disorder have greater knowledge of opioid overdose and ability to respond appropriately after receiving training in naloxone administration than peers who learn about opioid overdose and naloxone via an information booklet (Williams 2014). Some studies suggest individuals with a substance use disorder who participate in a brief 5-10 minute training or learn naloxone administration through social networks can respond appropriately to an overdose (Doe-Simkins 2014, Behar 2014).

Opioid overdose education delivered via computer or written pamphlets can increase knowledge and reduce behavioral risk factors (Sisson 2023, Dunn 2017, Berland 2019). Personalized computer-based OEND programs have been shown to decrease perceived treatment barriers and self-reported opioid use among individuals with a substance use disorder (Winhusen 2020). OEND program participation may increase adherence to medications that treat opioid use disorder (Jones 2021a). Participants in extended training programs are more likely to use naloxone in the short term; however, no difference in naloxone use remains one year after participation in either type of training (Jones 2022b).

Training first responders such as police, firefighters, and EMTs to administer naloxone may reduce time to overdose rescue, possibly decreasing overdose-related injury and death (Davis 2014c). Law enforcement officers and pharmacy students who participate in naloxone administration and overdose training report increases in knowledge and confidence in managing opioid overdose emergencies after program completion (Kwon 2020, Dahlem 2023, White 2021, Dahlem 2017, Purviance 2017, Wagner 2016). Implementing naloxone distribution programs within emergency department settings may increase access to naloxone among high-risk populations (Gunn 2018); however, allocating training time within already overloaded schedules for emergency department staff can be challenging (Gunn 2018). Prescribing of naloxone by primary care providers may be a way to expand access to individuals who are not part of a community-based approach (Behar 2018). Take home naloxone programs do not seem to increase opioid or substance use (Tse 2022, Katzman 2020, Chimbar 2018).

Naloxone services provided by pharmacists are beneficial beyond community pharmacy settings and should be considered to create more targeted future programs (e.g., for veterans affairs and academic medical centers) (Rawal 2023). Many pharmacists are knowledgeable and confident dispensing naloxone; however, one Ohio-based survey suggests barriers remain in understanding local and state laws (Thompson 2019). Additional barriers among pharmacists include education and training, workflow, and management support (Thakur 2019, Muzyk 2019). Among medical students, both online and in-person overdose trainings have been shown to be effective (Berland 2019, Berland 2017). Trainings on overdose response and naloxone administration can be incorporated broadly in current medical school curriculum (Taylor 2018) or specifically for pharmacy students (Kwon 2020). Input and perspectives from people who use drugs should be included when designing overdose education and naloxone distribution programs to improve program reach and effectiveness (Enich 2023).

Community-based naloxone distribution programs are cost-effective (Resko 2024, Cherrier 2022). U.S.-based and international analyses estimate that naloxone programs have large positive benefits for society, ranging from hundreds to tens of thousands of dollars (Cherrier 2022). Overdose education and naloxone distribution operating costs vary by program type and number of sites (Behrends 2022).

How could this strategy advance health equity? This strategy is rated potential to decrease disparities: suggested by intervention design. -+

Naloxone education and distribution programs have the potential to decrease disparities in naloxone distribution and access to reduce overdose deaths. Inequalities by race, geographic location, and economic status persist in overdose deaths (CDC-Disparities widen, Zhang 2018c). Most people who overdose are non-Hispanic whites, about 10% are non-Hispanic Blacks, and 8% are Hispanic (Salmond 2019). Experts attribute this demographic breakdown to the unconscious bias and prejudices of health care providers, who are more cautious prescribing opioids to non-white patients based on the prejudiced assumption that non-white patients are more likely to abuse or sell opioid prescription drugs (Salmond 2019). Individuals who exhibit mental health conditions are also more likely to use opioids (Salmond 2019). Providing naloxone and related education to family members of individuals with opioid use disorders is a cost-effective approach to increase access to naloxone for high-risk individuals. There is a need to reach family members of minoritized racial groups as attitudes among this group are more negative toward overdose response compared to their white counterparts (Resko 2024).

In the United States, opioid-related overdose death rates are much higher in rural areas compared to urban areas (Zhang 2018c). Administration of naloxone by life support personnel is low, even in areas with high overdose death rates. Policies that expand naloxone administration by EMTs and increase access for those at risk of overdose may reduce opioid-related overdose deaths in rural areas (Zhang 2018c). A study conducted in Massachusetts and Rhode Island found that areas encompassing large cities have higher naloxone kit distribution rates per opioid overdose deaths compared to non-urban areas that don’t encompass large cities (Zang 2021).

Adults who experience homelessness are disproportionately impacted by opioid overdoses and can benefit from naloxone education and distribution programs. An opioid overdose training and routine naloxone prescribing program at a homeless clinic in Pennsylvania, found that patients significantly increased their knowledge of opiate overdose after participating in the 15-minute education program. More research is needed to understand the barriers around naloxone fill rates, including housing, insurance, and other prescription use status (Pietrusza 2018). Opioid overdose rates are highest among individuals with less education and fewer employment opportunities (Judd 2023).

What is the relevant historical background? -+

Opioid overdose deaths have been increasing since 1999 (Freeman 2018). The rise in opioid overdose deaths began in the 1990s with a substantial increase in the prescription of both natural and semi-synthetic opioids because they were effective at managing chronic pain and falsely marketed to health care providers as non-addictive (CDC-Understanding the epidemic, Bennett 2021, Haffajee 2020). Prescription opioid sales increased fourfold between 1999 and 2008 (Judd 2023). Many patients who became addicted to prescribed opioids turned to non-prescribed forms of opioids, such as heroin, which lead to a second wave of opioid overdoses in 2010. In 2013, a third wave began when synthetic opioids, such as fentanyl, that are much more potent than other forms of opioids were combined with other drugs or counterfeit prescription pills, often unknown to the purchaser (CDC-Understanding the epidemic). In 2013, the U.S. Department of Health and Human Services declared the misuse of prescription opioids an epidemic. Four years later, in 2017 the opioid epidemic was declared a national public health emergency (Salmond 2019). Between 2020 and 2021, the opioid overdose death rate increased by over 15% and the synthetic opioid overdose death rate increased by over 22% (CDC-Understanding the epidemic).

The dramatic increase in opioid sales was the result of pharmaceutical companies that overproduced and oversupplied opioid drugs for huge profits, pharmacies that filled the prescriptions, and health care providers who overprescribed the medications (Judd 2023). In rural areas many physicians overprescribed opioids to patients who travel long distances for treatment, do not have the ability to attend frequent appointments, and do not have alternative pain management interventions in their area (Judd 2023).

Naloxone was first approved by the FDA in 1971; however, its use was primarily limited to hospitals or ambulances and was controlled by those in the health care and criminal justice systems. Despite the rise in medical prescription opioids often targeted at vulnerable populations, stigmatization of people who misuse opioids increased opposition to naloxone access and increased political, legal, financial, and logistical struggles faced by advocates for naloxone expansion (Bennett 2021). For decades advocates worked to overcome barriers to naloxone access and to reframe society’s response to drug use from a criminal justice-oriented approach to a public health approach. This narrative shift initially began to take effect as U.S. veterans struggled with opioid addiction while trying to manage chronic pain and as opioid use impacted many predominantly white, middle-class communities (Bennett 2021). The narrative shift has benefitted many white communities; however, predominantly Black and Hispanic communities are largely still treated with criminal justice-oriented policies and mindsets. By 2017, all 50 states in the U.S. have adopted some variation of naloxone access laws; however, more work needs to be done to address disparities in access and to continue to overcome stigma (Bennett 2021).

Equity Considerations -+

  • How does your community provide naloxone education and support naloxone distribution? Are naloxone take home kits readily available for community members? If not, why is that?
  • Who can you partner with to create or expand a naloxone education and distribution program in your community?
  • What do opioid related overdose death rates look like in your community? Who has access to naloxone and who still needs access? What changes can your community make to a naloxone education and distribution program to reach community members at high risk of opioid overdose?

Implementation Examples -+

As of September 2019, there are 17 states that have enacted naloxone co-prescribing laws that allow prescribers to prescribe naloxone to patients who meet overdose risk criteria (Haffajee 2020). In 2014, 644 local opioid overdose prevention programs in 30 states and Washington, D.C. provided community members with naloxone kits and training in proper use (CDC MMWR-Naloxone 2015). Many states provide civil and criminal immunity for both prescribers and administrators (PDAPS-Naloxone, Davis 2015). The Veterans Health Administration (VHA) has developed and implemented a national Opioid Overdose Education and Naloxone Distribution (OEND) at all VHA medical facilities (Oliva 2017).

Since November 2017, all 50 states have passed and implemented enhanced naloxone access laws with only 19 of those states mandating naloxone education training to pharmacists before they engage in independent naloxone dispensing and prescribing activities (Roberts 2019).

In November 2015, a nasal spray method of administering naloxone was approved by the U.S. Food and Drug Administration (FDA) along with the previously-approved injection method (US FDA-Naloxone 2015).

Take home naloxone (THN) kits are increasingly available through community pharmacy-based THN programs (Cid 2021).

Implementation Resources -+

CDC-Naloxone training 2023 - Centers for Disease Control and Prevention (CDC). Naloxone training.

CDC-Vital signs 2019 - Centers for Disease Control and Prevention (CDC). Vital signs. Life-saving naloxone from pharmacies.

HRC-Overdose - Harm Reduction Coalition (HRC). Overdose prevention.

NIDA-Naloxone - National Institute on Drug Abuse (NIDA). Naloxone.

NSC-Overdose - National Safety Council (NSC). Can you recognize the signs of an opioid overdose?

Pew-Naloxone access 2020 - The Pew Charitable Trusts (Pew). Expanded access to naloxone can curb opioid overdose deaths. 2020.

PHLR-Platt 2022 - Platt E. Naloxone overdoes prevention laws. Center for Public Health Law Research (PHLR). 2022.

Project DAWN - Project Dawn (Deaths Avoided With Naloxone). Ohio Department of Health. 2017.

SAMHSA-Community coalition 2023 - Substance Abuse and Mental Health Services Administration (SAMHSA). Engaging community coalitions to decrease opioid overdose deaths.

SAMHSA-Overdose - Substance Abuse and Mental Health Services Administration (SAMHSA). Opioid overdose prevention toolkit. 2018.

US DOJ BJA-Naloxone - U.S. Department of Justice (U.S. DOJ), Bureau of Justice Assistance (BJA). National Training and Technical Assistance Center. Law Enforcement Naloxone Toolkit.

Citations -+

* Journal subscription may be required for access.

Ashrafioun 2016* - Ashrafioun L, Gamble S, Herrmann M, Baciewicz G. Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods. Substance Abuse. 2016;37(1):76-81.

Behar 2014* - Behar E, Santos GM, Wheeler E, Rowe C, Coffin PO. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug and Alcohol Dependence. 2014;148:209-212.

Behar 2018* - Behar E, Bagnulo R, Coffin PO. Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review. Preventive Medicine. 2018;114:79-87.

Behrends 2022* - Behrends CN, Gutkind S, Winkelstein E, et al. Costs of opioid overdose education and naloxone distribution in New York City. Substance Abuse. 2022;43(1):692-698.

Bennett 2021* - Bennett AS, Elliott L. Naloxone’s role in the national opioid crisis — past struggles, current efforts, and future opportunities. Translational Research. 2021;234:43-57.

Berland 2017* - Berland N, Fox A, Tofighi B, Hanley K. Opioid overdose training with naloxone, an adjunct to basic life support for first-year medical students. Substance Abuse. 2017;38(2):123-128.

Berland 2019* - Berland N, Lugassy D, Fox A, et al. Use of online opioid overdose prevention training for first-year medical students: A comparative analysis of online vs in-person training. Substance Abuse. 2019;40(2):240-246.

CDC MMWR-Naloxone 2015 - Centers for Disease Control and Prevention (CDC). Opioid overdose prevention programs providing naloxone to laypersons: United States, 2014. Morbidity and Mortality Weekly Report (MMWR). 2015;64:631-635.

CDC-Disparities widen - Centers for Disease Control and Prevention (CDC). Vital signs. Drug overdose deaths rise, disparities widen.

CDC-Understanding the epidemic - Centers for Disease Control and Prevention (CDC). Understanding the opioid overdose epidemic.

Cherrier 2022 - Cherrier N, Kearon J, Tetreault R, Garasia S, Guindon E. Community distribution of naloxone: A systematic review of economic evaluations. PharmacoEconomics - Open. 2022;6(3):329-342.

Chimbar 2018* - Chimbar L, Moleta Y. Naloxone effectiveness: A systematic review. Journal of Addictions Nursing. 2018;29(3):167-171.

Cid 2021 - Cid A, Daskalakis G, Grindrod K, Beazely MA. What is known about community pharmacy-based take-home naloxone programs and program interventions? A scoping review. Pharmacy. 2021;9(1):30.

Clark 2014 - Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. Journal of Addiction Medicine. 2014;8(3):153-163.

Dahlem 2017* - Dahlem CHG, King L, Anderson G, et al. Beyond rescue: Implementation and evaluation of revised naloxone training for law enforcement officers. Public Health Nursing. 2017;34(6):516-521.

Dahlem 2023 - Dahlem CH, Patil R, Khadr L, et al. Effectiveness of take ACTION online naloxone training for law enforcement officers. Health and Justice. 2023;11(1):47.

Davis 2014b* - Davis CS, Southwell JK, Niehaus VR, Walley AY, Dailey MW. Emergency medical services naloxone access: A national systematic legal review. Academic Emergency Medicine. 2014;21(10):1173-1177.

Davis 2014c* - Davis CS, Ruiz S, Glynn P, Picariello G, Walley AY. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. American Journal of Public Health. 2014;104(8):e7-e9.

Davis 2015* - Davis CS, Carr D. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug and Alcohol Dependence. 2015;157:112-120.

Doe-Simkins 2014 - Doe-Simkins M, Quinn E, Xuan Z, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: A retrospective cohort study. BMC Public Health. 2014;14:297.

Dunn 2017 - Dunn KE, Yepez-Laubach C, Nuzzo PA, et al. Randomized controlled trial of a computerized opioid overdose education intervention. Drug and Alcohol Dependence. 2017;173(Suppl 1):S39-S47.

Enich 2023 - Enich M, Flumo R, Campos S, et al. Overdose education and naloxone distribution program design informed by people who use drugs and naloxone distributors. Preventive Medicine Reports. 2023;35:102374.

Evoy 2021 - Evoy KE, Hill LG, Davis CS. Considering the potential benefits of over-the-counter naloxone. Integrated Pharmacy Research and Practice. 2021;10:13-21.

Freeman 2018* - Freeman PR, Hankosky ER, Lofwall MR, Talbert JC. The changing landscape of naloxone availability in the United States, 2011 – 2017. Drug and Alcohol Dependence. 2018;191:361-364.

Giglio 2015 - Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: A meta-analysis. Injury Epidemiology. 2015;2(10):1-9.

Gunn 2018 - Gunn AH, Smothers ZPW, Schramm-Sapyta N, et al. The emergency department as an opportunity for naloxone distribution. Western Journal of Emergency Medicine. 2018;19(6):1036-1042.

Haffajee 2020* - Haffajee RL, Cherney S, Smart R. Legal requirements and recommendations to prescribe naloxone. Drug and Alcohol Dependence. 2020;209:107896.

Heavey 2018* - Heavey SC, Burstein G, Moore C, Homish GG. Overdose education and naloxone distribution program attendees: Who attends, what do they know, and how do they feel? Journal of Public Health Management and Practice. 2018;24(1):63-68.

Jones 2021a* - Jones JD, Campbell AN, Brandt L, et al. Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder. Substance Abuse. 2021;42(4):407-411.

Jones 2022b* - Jones JD, Campbell AN, Brandt L, et al. A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder. Drug and Alcohol Dependence. 2022;237:109505.

Judd 2023* - Judd D, King CR, Galke C. The opioid epidemic: A review of the contributing factors, negative consequences, and best practices. Cureus. 2023;15(7):e41621.

Katzman 2020 - Katzman JG, Takeda MY, Greenberg N, et al. Association of take-home naloxone and opioid overdose reversals performed by patients in an opioid treatment program. JAMA Network Open. 2020;3(2):e200117.

Kulbokas 2021 - Kulbokas V, Hanson KA, Smart MH, et al. Academic detailing interventions for opioid-related outcomes: A scoping review. Drugs Context. 2021;10:1-20.

Kwon 2020 - Kwon M, Moody AE, Thigpen J, Gauld A. Implementation of an opioid overdose and naloxone distribution training in a pharmacist laboratory course. American Journal of Pharmaceutical Education. 2020;84(2):231-238.

Lewis 2016* - Lewis DA, Park JN, Vail L, et al. Evaluation of the overdose education and naloxone distribution program of the Baltimore Student Harm Reduction Coalition. American Journal of Public Health. 2016;106(7):1243-1246.

Lott 2016 - Lott DC, Rhodes J. Opioid overdose and naloxone education in a substance use disorder treatment program. The American Journal on Addictions. 2016;25(3):221-226.

Muzyk 2019* - Muzyk A, Smothers ZPW, Collins K, MacEachern M, Wu LT. Pharmacists’ attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature. Substance Abuse. 2019;40(4):476-483.

NPHL 2021 - Network for Public Health Law Research (NPHL). Legal interventions to reduce overdose mortality: Naloxone access laws. 2021.

NPHL-Good Samaritan laws - The Network for Public Health Law (NPHL). Legal interventions to reduce overdoes mortality: Overdose Good Samaritan laws.

NPHL-Naloxone access laws - The Network for Public Health Law (NPHL). Legal interventions to reduce overdose mortality: Naloxone access laws.

NSC-Dane County 2015 - Safe Communities America. Madison-Dane County, Wisconsin: A coordinated response to stop the drug overdose epidemic. An NSC safe community in action. National Safety Council (NSC).

Oliva 2017 - Oliva EM, Christopher MLD, Wells D, et al. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration’s national program. Journal of the American Pharmacists Association. 2017;57(Suppl 2):S168-S179.e4.

PDAPS-Naloxone - Prescription Drug Abuse Policy System (PDAPS). Naloxone overdose prevention laws.

Pietrusza 2018* - Pietrusza LM, Puskar KR, Ren D, Mitchell AM. Evaluation of an opiate overdose educational intervention and naloxone prescribing program in homeless adults who use opiates. Journal of Addictions Nursing. 2018;29(3):188-195.

Purviance 2017* - Purviance D, Ray B, Tracy A, Southard E. Law enforcement attitudes towards naloxone following opioid overdose training. Substance Abuse. 2017;38(2):177-182.

Rawal 2023 - Rawal S, Osae SP, Cobran EK, Albert A, Young HN. Pharmacists’ naloxone services beyond community pharmacy settings: A systematic review. Research in Social and Administrative Pharmacy. 2023;19(2):243-265.

Razaghizad 2021* - Razaghizad A, Windle SB, Filion KB, et al. The effect of overdose education and naloxone distribution: An umbrella review of systematic reviews. American Journal of Public Health. 2021;111(8):e1-e12.

Resko 2024 - Resko SM, Pasman E, Hicks DL, et al. Naloxone knowledge and attitudes towards overdose response among family members of people who misuse opioids. Journal of Community Health. 2024;49:70-77.

Roberts 2019* - Roberts AW, Carpenter DM, Smith A, Look KA. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists. Research in Social and Administrative Pharmacy. 2019;15(2):222-225.

Salmond 2019 - Salmond S, Allread V. A population health approach to America’s opioid epidemic. Orthopaedic Nursing. 2019;38(2):95-108.

SAMHSA-Overdose - Substance Abuse and Mental Health Services Administration (SAMHSA). Opioid overdose prevention toolkit. 2018.

Sisson 2023* - Sisson ML, Azuero A, Chichester KR, et al. Preliminary effectiveness of online opioid overdose and naloxone administration training and impact of naloxone possession on opioid use. Drug and Alcohol Dependence. 2023;249:110815.

Strang 2008* - Strang J, Manning V, Mayet S, et al. Overdose training and take-home naloxone for opiate users: Prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction. 2008;103(10):1648-57.

Taylor 2018* - Taylor JL, Rapoport AB, Rowley CF, Mukamal KJ, Stead W. An opioid overdose curriculum for medical residents: Impact on naloxone prescribing knowledge and attitudes. Substance Abuse. 2018;39(3):371-376.

TFAH-Levi 2013 - Levi J, Segal LM, Miller AF. Prescription drug abuse: strategies to stop the epidemic. Trust for America’s Health (TFAH). 2013.

Thakur 2019* - Thakur T, Frey M, Chewning B. Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review. Journal of the American Pharmacists Association. 2019;60(1):178-194.

Thompson 2019 - Thompson EL, Rao PSS, Hayes C, Purtill C. Dispensing naloxone without a prescription: Survey evaluation of Ohio pharmacists. Journal of Pharmacy Practice. 2019;32(4):412-421.

Tse 2022* - Tse WC, Djordjevic F, Borja V, et al. Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a ‘moral hazard’ associated with naloxone supply. International Journal of Drug Policy. 2022;100:103513.

UHS-Naloxone on campus - University Health Services. Naloxone on campus.

US FDA-Naloxone 2015 - U.S. Food and Drug Administration (U.S. FDA). FDA moves quickly to approve easy-to-use nasal spray (Naloxone) to treat opioid overdose. 2015.

Wagner 2016* - Wagner KD, Bovet LJ, Haynes B, Joshua A, Davidson PJ. Training law enforcement to respond to opioid overdose with naloxone: Impact on knowledge, attitudes, and interactions with community members. Drug and Alcohol Dependence. 2016;165:22-28.

Walley 2013* - Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ. 2013;346:f174.

White 2021* - White MD, Perrone D, Malm A, Watts S. Narcan cops: Officer perceptions of opioid use and willingness to carry naloxone. Journal of Criminal Justice. 2021;72:101778.

Williams 2014* - Williams AV, Marsden J, Strang J. Training family members to manage heroin overdose and administer naloxone: Randomized trial of effects on knowledge and attitudes. Addiction. 2014;109(2):250-259.

Winhusen 2020 - Winhusen T, Wilder C, Lyons MS, et al. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug and Alcohol Dependence. 2020;216:108265.

Zang 2021* - Zang X, Macmadu A, Krieger MS, et al. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. International Journal of Drug Policy. 2021;98:103435.

Zhang 2018c* - Zhang X, Marchand C, Sullivan B, Klass EM, Wagner KD. Naloxone access for Emergency Medical Technicians: An evaluation of a training program in rural communities. Addictive Behaviors. 2018;86:79-85.